ArticleJournal of community genetics2026
Screening for beta thalassemia trait in a heterogeneous university-based population in Delhi-NCR, India.
Article in Journal of community genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThalassemia is a major monogenic blood disorder, with India bearing a substantial burden. Although carrier screening is the most effective preventive strategy, inconsistent criteria, borderline HbA2 values, diverse mutations, and limited HbE detection hinder effectiveness. This study determines the prevalence of molecularly confirmed beta thalassemia trait (BTT) and HbE detected through a large-scale screening approach among young adults in Delhi-National Capital Region (NCR) and develops a potential scalable model for university-based carrier detection.
methodsWe recruited 4886 young adults aged 18-35 years from universities in Delhi-NCR. All blood samples underwent CBC and HPLC analysis, with selected samples subjected to genetic analysis using ARMS-PCR and Sanger sequencing.
resultsThe prevalence of molecularly confirmed BTT and HbE trait detected through the study screening approach was 1.6% and 0.4%, respectively. Overall, 2% showed elevated HbA2 with low MCV and MCH, while 5.1% of carriers had borderline HbA2. Five common beta thalassemia mutations accounted for 84.8% of cases. Nearly 21% of samples with HbA2 4-9% showed no mutations on genetic testing. HbA2 4-9% plus low MCV and MCH showed the highest PPV, with 92% sensitivity and 88% specificity. No significant differences in BTT distribution were observed by region, religion, or social category.
conclusionsLarge-scale screening for BTT among young adults in university-based settings may facilitate early carrier identification. HbA2 levels of 4-9% combined with low MCV and MCH appear to be an effective first-tier screening criterion, while further criteria are needed to identify and prioritize individuals with borderline HbA2 levels (3.2-3.9%) for molecular confirmation. Future studies should focus on developing and validating robust, context-appropriate population-level screening protocols for BTT in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.